01 / DESIGN
What was studied?
Diabetic mouse models and stressed human cardiac endothelial cells were examined, including partial PRKN silencing and lysosomal blockade.
02 / FINDINGS
What did the researchers report?
Treatment-associated endpoints suggested less microvascular damage and lipid peroxidation. Partial PRKN silencing produced less favorable cell measurements, but some treatment differences remained.
03 / LIMITS
How should it be interpreted?
The authors did not establish that PRKN was required. Receptor dependence, mitochondrial turnover and independence from systemic metabolic change remained unresolved.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.